EGFR and non-small cell lung carcinoma: In September 2021, the FDA granted accelerated approval to mobocertinib (TAK-788) for patients with locally advanced or metastatic NSCLC with EGFR Ex20ins mutations whose disease has progressed on or after platinum-based chemotherapy.